197 related articles for article (PubMed ID: 34485908)
41. Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma.
Nguyen TTT; Shang E; Schiffgens S; Torrini C; Shu C; Akman HO; Prabhu VV; Allen JE; Westhoff MA; Karpel-Massler G; Siegelin MD
Clin Cancer Res; 2022 May; 28(9):1881-1895. PubMed ID: 35417530
[TBL] [Abstract][Full Text] [Related]
42. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
Liu J; Viswanadhapalli S; Garcia L; Zhou M; Nair BC; Kost E; Rao Tekmal R; Li R; Rao MK; Curiel T; Vadlamudi RK; Sareddy GR
Oncotarget; 2017 Jul; 8(30):50002-50014. PubMed ID: 28654894
[TBL] [Abstract][Full Text] [Related]
44. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
45. Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models.
Wu Y; Chen X; Wang L; Zhou X; Liu Y; Ji D; Ren P; Zhou GG; Zhao J
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560800
[TBL] [Abstract][Full Text] [Related]
46. E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors.
Jordaan G; Liao W; Sharma S
BMC Cancer; 2013 Feb; 13():88. PubMed ID: 23432814
[TBL] [Abstract][Full Text] [Related]
47. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.
Ellis L; Bots M; Lindemann RK; Bolden JE; Newbold A; Cluse LA; Scott CL; Strasser A; Atadja P; Lowe SW; Johnstone RW
Blood; 2009 Jul; 114(2):380-93. PubMed ID: 19383971
[TBL] [Abstract][Full Text] [Related]
48. Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
Mamdani H; Jalal SI
Front Cell Dev Biol; 2020; 8():582370. PubMed ID: 33163495
[TBL] [Abstract][Full Text] [Related]
49. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
50. PELP1 promotes glioblastoma progression by enhancing Wnt/β-catenin signaling.
Sareddy GR; Pratap UP; Viswanadhapalli S; Venkata PP; Nair BC; Krishnan SR; Zheng S; Gilbert AR; Brenner AJ; Brann DW; Vadlamudi RK
Neurooncol Adv; 2019; 1(1):vdz042. PubMed ID: 32309805
[TBL] [Abstract][Full Text] [Related]
51. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
Lauffer BE; Mintzer R; Fong R; Mukund S; Tam C; Zilberleyb I; Flicke B; Ritscher A; Fedorowicz G; Vallero R; Ortwine DF; Gunzner J; Modrusan Z; Neumann L; Koth CM; Lupardus PJ; Kaminker JS; Heise CE; Steiner P
J Biol Chem; 2013 Sep; 288(37):26926-43. PubMed ID: 23897821
[TBL] [Abstract][Full Text] [Related]
52. HDAC inhibitors Panobinostat and Romidepsin enhance
Schnell AP; Kohrt S; Aristodemou A; Taylor GP; Bangham CRM; Thoma-Kress AK
Front Immunol; 2022; 13():978800. PubMed ID: 36052071
[TBL] [Abstract][Full Text] [Related]
53. Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma.
Phimmachanh M; Han JZR; O'Donnell YEI; Latham SL; Croucher DR
Front Cell Dev Biol; 2020; 8():578770. PubMed ID: 33117806
[TBL] [Abstract][Full Text] [Related]
54. Unique anti-glioblastoma activities of hypericin are at the crossroad of biochemical and epigenetic events and culminate in tumor cell differentiation.
Dror N; Mandel M; Lavie G
PLoS One; 2013; 8(9):e73625. PubMed ID: 24066060
[TBL] [Abstract][Full Text] [Related]
55. Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Alejo S; Palacios BE; Venkata PP; He Y; Li W; Johnson JD; Chen Y; Jayamohan S; Pratap UP; Clarke K; Zou Y; Lv Y; Weldon K; Viswanadhapalli S; Lai Z; Ye Z; Chen Y; Gilbert AR; Suzuki T; Tekmal RR; Zhao W; Zheng S; Vadlamudi RK; Brenner AJ; Sareddy GR
Neuro Oncol; 2023 Jul; 25(7):1249-1261. PubMed ID: 36652263
[TBL] [Abstract][Full Text] [Related]
56. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme.
Li Q; Dong C; Cui J; Wang Y; Hong X
J Exp Clin Cancer Res; 2018 Oct; 37(1):265. PubMed ID: 30376874
[TBL] [Abstract][Full Text] [Related]
57. Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents.
Tapadar S; Fathi S; Wu B; Sun CQ; Raji I; Moore SG; Arnold RS; Gaul DA; Petros JA; Oyelere AK
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33114147
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic significance of estrogen receptor β agonists in gliomas.
Sareddy GR; Nair BC; Gonugunta VK; Zhang QG; Brenner A; Brann DW; Tekmal RR; Vadlamudi RK
Mol Cancer Ther; 2012 May; 11(5):1174-82. PubMed ID: 22442308
[TBL] [Abstract][Full Text] [Related]
59. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
60. CLPTM1L induces estrogen receptor β signaling-mediated radioresistance in non-small cell lung cancer cells.
Li H; Che J; Jiang M; Cui M; Feng G; Dong J; Zhang S; Lu L; Liu W; Fan S
Cell Commun Signal; 2020 Sep; 18(1):152. PubMed ID: 32943060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
